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Estrogen receptor alpha positive (ERα+) breast cancer cells proliferate and 
survive by utilizing multiple pathways.  Thus, combination chemotherapies targeting 
multiple pathways may be used to decrease ERα+ breast cancer cell density.   Tamoxifen 
(Tam), an estrogen antagonist, has been used for over 30 years to inhibit ERα+ breast 
cancer proliferation.  Naringenin (Nar), a flavonoid, has been shown to reduce the 
proliferation of ERα+ breast cancer cells by inhibiting extracellular signal-regulated 
kinases 1/2 (ERK 1/2) and AKT.   
In our studies, we investigated the effects of a combination of Tam and Nar on 
MCF-7 ERα+ breast cancer cells.  We showed that Tam and Nar significantly inhibited 
cellular proliferation and viability by flow cytometry analysis when compared to Tam 
alone.  Proliferation was inhibited by the reduction of expression of AKT and ERK 1/2, 
as determined by immunoblot analysis.   
We have investigated the combination of Nar and Tam on Tam resistant (Tam-R) 
cells.  Our results demonstrate that Nar alone impaired cellular proliferation and viability 
in Tam-R cells.  In the absence of lipophilic compounds, Nar eliminated the 
phosphorylation of ERK 1/2, as determined by immunoblot analysis. 
Taken together, our results suggest that a combination treatment of Nar and Tam 
is more effective in inhibiting cellular proliferation and viability than Tam alone in ER+
	  
	  
breast cancer cells.  This combination treatment has the potential to improve the efficacy 
of breast cancer chemotherapy regimens.
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CHAPTER I 
 
INTRODUCTION 
 
 
Breast carcinoma is a devastating disease that is predicted to claim over 40,000 
lives in the US in 2013 (1).  Furthermore, over 240,000 new cases of breast cancer will be 
diagnosed in 2013 (1).  Approximately two thirds of breast cancer is estrogen receptor 
positive (ER+) (2). There are two characterized estrogen receptors, ERα and ERβ, yet 
ERα is the only receptor that promotes proliferation in ER+ breast cancer cells (3). 
Estrogen receptor α domains 
ERα is a nuclear receptor with six functional domains (A – F), four that regulate 
the ERα activity.  On the N terminus of ERα, the A/B domain contains the ligand-
independent transcriptional activation function 1 (AF1). Phosphorylation at the AF1 
allows the ERα to be constitutively active, even in the absence of estrogen (4,5) (Figure 
1).   
On the other hand, the C terminus of ERα contains the E/F domains, which harbor 
the ligand-dependent transcriptional activation function (AF2).  Estrogen stimulates 
transcriptional activity of the ERα by binding to the AF2 (4,5).   Although these regions 
are activated by different stimuli, AF1 works with AF2 synergistically to promote ligand 
dependent transcription of estrogen responsive genes (6) (Figure 1). 
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Figure 1. Schematic of ERα. ERα has 6 domains.  A/B domain contains the AF1, C is 
the DNA binding domain, D is the hinge domain, E/F domains harbor the AF2.  
 
 
There are various mechanisms that promote the survival and growth of ERα+ 
breast cancer.  Specifically, ERα+ breast cancers can utilize the nongenomic and 
genomic pathways of the ERα, the phosphoinositide 3-kinase (PI3K), and the mitogen 
activated protein kinase (MAPK) pathways. 
ERα + breast cancer proliferation and the estrogen/ERα complex 
The primary pathway for ERα+ breast cancer cellular proliferation begins with 
the formation of the estrogen/ERα complex.  When estrogen enters its target cell, it binds 
to the AF2 domain of the ERα, and the estrogen/ERα complex can proceed down one of 
two pathways: the genomic or non-genomic pathway, both of which produce pro-
proliferative effects.   
The non-genomic pathway of the estrogen/ERα complex produces rapid 
responses after estrogen binds to the receptor.  These rapid responses are mediated 
through ERα’s that are localized at the plasma membrane. Once estrogen binds to ERα, 
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the complex disassociates from cell membrane and interacts with cytoplasmic kinase 
pathways (7,8). 
Alternatively, the genomic pathway works over a period of hours.  In the classical 
genomic model, the estrogen/ERα complex binds to the estrogen response element (ERE) 
on estrogen responsive genes.  Coregulators are then recruited to the promoter region to 
alter the rate of transcription (9). Estrogen responsive genes include those involved in cell 
proliferation, cell cycle control, transcriptional regulation, and metabolic processes (10).  
ERα+ breast cancer proliferation and PI3K 
In ERα+ breast cancers, >30% of tumors develop a mutation in the PI3K 
pathway, resulting in uncontrolled proliferation and resistance to apoptosis (11-19). 
Activation of tyrosine kinase growth factor receptors (RTK) stimulates the PI3K pathway 
(20-25).  The activated intracellular portion of the RTK serves as a “docking station” (26) 
for intracellular proteins such as PI3K.   At the cell membrane, activated PI3K 
phosphorylates phosphatidylinositol-4,5-bisulfate (PIP2), converting it to 
phosphatidylinositol-3,4,5-trisulfate (PIP3) (27).   Next, PIP3 recruits AKT (28-31).  
Activation of AKT requires two phosphorylation events; first, PDK phosphorylates AKT 
at Thr308 resulting in partial activation.  Next, proteins such as mTOR complex 2 
(TORC2) (32) or integrin linked-kinase (ILK) (33) can phosphorylate AKT at Ser473 to 
achieve full activation.  Once AKT is fully activated, it can activate its downstream 
substrates, which control cell cycle progression and transcription (34) (Figure 2).  
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Figure 2. Overview of the PI3K pathway. Activated RTK recruits PI3K.  Activated 
PI3K phosphorylates PIP2, resulting in an active PIP3, which recruits AKT.  
Phosphorylation events by various proteins, including PDK, activate AKT, resulting in 
cell proliferation and survival. 
 
 
ERα+ breast cancer proliferation and MAPK 
In breast cancer, the Mitogen Activated Protein Kinase (MAPK) cascade has been 
found to be constitutively active (35).  Similar to the PI3K pathway, the MAPK pathways 
are involved in the regulation of survival and proliferation.  The MAPK ERK 1/2 
pathway, which is activated by growth factors such as estrogen (36), includes Raf, the 
MEK 1/2, and the ERK 1 and 2 (ERK 1/2).  ERK 1/2 have numerous substrates, 
including RSK, which promote cellular proliferation and survival (37) (Figure 3). 
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Figure 3. Overview of the MAPK ERK 1/2 pathway. An active RTK stimulates RAS, 
which activates Raf.  Raf phosphorylates MEK 1/2, which phosphorylates ERK 1/2.  
ERK 1/2 can translocate to the nucleus to phosphorylate various transcription factors. 
  
 
Cross talk between ERα and kinase pathways 
ERα, PI3K, and MAPK pathways regulate one another.  It is well documented 
that the kinase pathways influence the transcriptional activity of the ERα.  
Phosphorylated ERK 1/2 can phosphorylate ERα on serine 118 (38), which leads to 
ligand-independent activation of ERα at the AF1 domain (39).  Additionally, AKT 
phosphorylates ERα on serine 167, causing ligand-independent activation of ERα 
(40,41).   ERα ligand-independent activation results in recruitment of co-activators to 
promote transcription of target genes (42) (Figure 4).  
Furthermore, the action of the non-genomic ERα/estrogen complex activates 
numerous pathways, including the PI3K and MAPK pathways (43, 44) (Figure 4).   This 
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bi-directional stimulation between ERα and kinase pathways renders a cancer that is 
difficult to treat. 
 
 
 
Figure 4. Crosstalk between kinase pathways and ERα.  The cytosolic estrogen/ERα 
complex can activate ERK 1/2 and AKT, which further phosphorylate the ERα to 
promote ligand-independent transcription.  P: phosphate group.  E: estrogen. 
 
 
ERα+ breast cancer treatments: endocrine therapy 
Endocrine therapy has resulted in reduced mortality and decreased reoccurrence 
of ER+ breast cancer (45).   Because of high efficacy and tolerance, as well as more than 
30 years of positive clinical results, tamoxifen (Tam) is the most prescribed endocrine 
therapy drug to treat ER+ breast cancer (46). Directly competing with estrogen, a 
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metabolite of Tam, 4-hydroxytamoxifen (4-OHT), binds to the ERα, and the resulting 
complex binds to the ERE, inhibiting expression of estrogen responsive genes, and 
ultimately causing cell cycle arrest (47-49).   
Tam has been said to be “the most important drug to be developed in the history 
of breast cancer” (50).  Yet, Tam is not without its limitations.  Tam treatment does not 
result in cell death; rather it arrests the cells the G1 phase of the cell cycle (51). In 
addition, thirty percent of ER+ breast cancer tumors do not respond to Tam, and those 
that do eventually develop resistance.  Previous studies have found that over activation of 
the MAPK and PI3K pathways during Tam treatment may cause Tam resistance via 
ligand-independent activation of the ERα, decreasing the overall rate of ER+ breast 
cancer survival (52).   
ERα+ breast cancer treatment: flavonoids      
Because of their ability to promote proliferation and activate the ERα, PI3K and 
MAPK pathways have become a therapeutic target for breast cancer (53,54).  In our lab, 
we have identified naringenin (Nar), a grapefruit flavonoid, as an inhibitor of both the 
PI3K and MAPK pathways. Nar has been shown to inhibit the phosphorylation of both 
ERK 1/2 and AKT in MCF-7 ERα+ breast cancer cells (55).  
Additionally, studies have shown that Nar inhibits estrogen-dependent 
proliferation by competing with estrogen to bind to ERα (56).  When bound to ERα, Nar 
decreases the rapid activation of ERα at the plasma membrane by quickly disassociating 
it from caveolin-1 at the cell membrane (Figure 4) (57).  This interaction abolishes the 
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ability of ERα to activate the kinase pathways, and has been shown to promote apoptosis 
(58). 
Apoptosis  
 Apoptosis is a pathway that is stimulated by various stimuli and is regulated by 
caspases (cysteine aspartyl-specific protease).  Cytochrome c, a central player in 
apoptosis, resides in the inner membrane of the mitochondria.  Pro-apoptotic signals 
affect the mitochondrial membrane, resulting in cytochrome c release into the cytosol, 
where cytochrome c associates with the Apaf-1 protein to create the apoptosome.  The 
apoptosome then cleaves initiator caspases, such as caspase 9, resulting in activation of 
the caspase.  From there, activated initiator caspases cleave to activate executioner 
caspases, such as caspases 3, 6, and 7. Active executioner caspases eventually cleave 
important cellular components such as ICAD (inhibitor of caspase-activated DNAase), 
which frees the DNase, resulting in DNA fragmentation (59). 
Tam and Nar as combination therapy  
Inhibitors of single kinases or pathways are rarely clinically successful (60), and 
estrogen-antagonists such as Tam often lead to resistance. Combination therapies have 
the potential to fully inhibit tumors by promoting apoptosis and overcome or avoid 
resistance (52).  Currently, combination therapies using endocrine therapy and kinase 
inhibitors for breast cancer are being investigated (61) and may be the future of ERα+ 
breast cancer treatments.   
To inhibit ERα+ breast cancer cell proliferation in cell culture, Nar in 
combination with Tam appears ideal.  Tam inhibits ligand-dependent activation of the 
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ERα by acting as an estrogen antagonist.   Nar inhibits ERK 1/2 and Akt 
phosphorylation, which prohibits ligand-independent activation the ERα. Together as a 
combination therapy, Tam and Nar (Tam+Nar) would target multiple pathways that 
promote ER+ breast cancer cell proliferation and survival.   
Tam resistance and Nar 
As mentioned earlier, endocrine therapy resistance often occurs in ERα+ breast 
cancer cells.  This has been speculated as the cause of the ERK1/2 pathway 
phosphorylating of the ERα (52).  Studies have demonstrated that inhibition of the ERK 
1/2 activity in Tam-R cells restored Tam sensitivity (60). Studies have also shown that 
the inhibition of PI3K has reversed hormone therapy resistance (62).  Because Nar 
inhibits the activity of ERK 1/2 and AKT, Nar may restore Tam sensitivity to Tam-R 
cells.    
In our lab, we have developed Tam-R MCF-7 ERα+ breast cancer cells. These 
Tam-R cells were shown to have a constitutively active ERK 1/2 (unpublished data). By 
subjecting Tam-R cells to Nar treatment, ERK 1/2 phosphorylation may be inhibited and 
apoptosis could occur, demonstrating that Nar could be an effective treatment for Tam-R 
cells.
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CHAPTER II 
 
MATERIALS AND METHODS 
 
 
Materials 
The MCF-7 cell line was purchased from ATCC.  Tissue culture materials were 
from Gibco (Grand Island, NY).  Nar and 4-OHT were obtained from Sigma Aldrich (St. 
Louis, MO).  Guava Via-Count Reagent was purchased from Millipore (Billerica, MA).  
Phospho-p44/42 MAP kinase (Thr202/Tyr204), p44/42 MAP kinase, phospho-AKT (Ser473), 
and Akt antibodies were purchased from Cell Signaling Technology (Beverly, MA).   
ERα antibody was purchased from Santa Cruz Biotechnology (Dallas, TX ).  Actin 
antibody was obtained from Abcam (Cambridge, UK).  Anti-mouse and anti-rabbit 
horseradish peroxidase conjugated secondary antibodies were purchased from Sigma 
Aldrich.  AlexaFluor 488 conjugated Goat anti-Rabbit secondary antibody was obtained 
from Jackson ImmunoResearch (West Grove, PA).  The enhanced chemiluminescence 
(ECL) detection kit was from ThermoScientific (Waltham, MA).   
Cell culture 
Various media formulations were used during these studies.  MCF-7 and Tam-R 
cells were maintained in either Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% Fetal Bovine Serum (FBS), 0.01 mg/mL bovine insulin, and 100 
U/mL penicillin/streptomycin, or phenol red-free Dulbecco’s Modified Eagle Medium  
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(PRF-DMEM) supplemented with 10% charcoal-stripped FBS.  Tam-R media was 
supplemented with 100 nM Tam.  MCF-7 and Tam-R cells were maintained at 37° C 
with 5% CO2.  Media was replaced every 2 days, and cells were passed once they 
attained 80% confluence.  
Immunoblot analysis 
Cell lysates were prepared as previously described (53).  Protein concentrations of 
whole cell lysates were determined by Bradford Protein Concentration Assay (Bio-Rad, 
Hercules, California).  Samples were heated at 95°C for five minutes, separated by 10% 
SDS-PAGE, and transferred overnight to Immobilon-P membranes (Millipore).  
Membranes were incubated with the antibody of interest and visualized by Bio-Rad 
ChemiDoc XRS system using an enhanced chemiluminescent (ECL) kit.  The resulting 
bands were quantified using the densitometry feature in the Quantity One analysis 
software. 
Via-Count viability assay 
Treated cells were washed twice with PBS and subjected to trypsin.  Cells were 
centrifuged at 5000 x g for 5 min, supernatants were discarded and cells resuspended in 
PBS.  A 1:20 dilution of cells was prepared in ViaCount Reagent and incubated for 5 min 
in the dark. Viability was analyzed by Guava easy-CyteTM Flow Cytometry (Millore) 
using the ViaCount software. 
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Immunofluorescence 
Treated cells were fixed in 3.7% formaldehyde for 15 min, washed and then 
permeabilized in 0.25% Triton-X solution for 5 minutes.  Cells were blocked for 15 
minutes in a 5% goat serum, 1%BSA solution in PBS.  Cells were treated with primary 
antibody of interest at a 1:100 dilution for an h at RT.  Cells were washed 3 times in PBS 
and placed in secondary for an h in the dark.   Cells were washed and treated with a 
1:1000 DAPI solution for 5 min.  Coverslips were mounted onto slides using Dako 
mounting solution. 
Statistical analysis 
Data are stated as means ± SEM.  The significance of comparing means was 
assessed by two-way analysis of Student’s t-test (StatPlus, AnalystSoft).  
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CHAPTER III 
 
RESULTS 
 
 
Both Tam and Nar independently inhibit cell proliferation 
 Tam has been shown to inhibit MCF-7 cellular proliferation by inducing cell 
cycle arrest (47-49).  Nar, a kinase inhibitor, has been shown to inhibit cellular 
proliferation in MCF-7 cells by inhibiting pro-proliferation pathways, PI3K and MAPK 
(55, 69).  To determine the time course of inhibition, we treated MCF-7 cells with either 
100 nM Tam or 250 μM Nar for 2 – 5 days and assayed for cell density. Both Tam and 
Nar treatment reduced cell density on days 2, 4, and 5 of treatment when compared to 
control, with the greatest reduction on Day 4 (Figure 5A, B). 
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A.      
B.     
 
Figure 5. Tam and Nar alone inhibit cell density.  MCF-7 cells were grown in full 
medium in the presence of 4-OHT (100 nM) (Panel A) or Nar (250 μM) (Panel B).  Cell 
density (cells/ml) was determined by flow cytometry.  Results are the means ± SEM of 
three independent experiments.  Significance at P < 0.05 was compared to vehicle control 
(*).  
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Tam+Nar impairs cell density greater than Tam alone 
Combination treatments are often used to treat cancer.  Particularly, a 
combination of kinase inhibitors and ERα inhibitors has been investigated in the 
treatment of ERα+ breast cancer, in both experimental and clinical settings (61,62). 
Because Tam and Nar alone inhibit cell density, we wanted to determine the effects on 
cell density of a combination of Tam+Nar compared to the current clinical treatment: 
Tam alone.  To date, there have been no studies on the use of Tam and Nar as a 
combination treatment. 
To investigate whether Tam+Nar inhibits cell density greater than Tam alone, we 
treated MCF-7 cells with 100 nM Tam or a combination of 100 nM Tam and 250 μM Nar 
for 2 - 5 days.   When compared to Tam alone, Tam+Nar inhibited cell density on days 2 
- 5 (Figure 6).   
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Figure 6. Tam+Nar inhibits proliferation greater than Tam alone.  MCF-7 cells were 
grown in full medium in the presence of 4-OH-Tam (100 nM) or in 4-OH-Tam and Nar 
(250 μM).  Cell density (cells/ml) was determined by flow cytometry.  Results are the 
means ± SEM of three independent experiments. Significance at P < 0.05 was compared 
to Tam (*). 
 
 
Tam+Nar impairs cell viability greater than Tam alone 
To investigate the effect of Tam+Nar on ER+ breast cancer cell viability, we 
treated MCF-7 cells with 100 nM Tam, 250 μM Nar, or a combination of the two for 2 - 
5 days.  As expected, Tam treatment did not show a significant decrease in cell viability, 
which confirmed the cytostatic behavior of Tam.  Nar treatment significantly reduced 
(40%) cell viability by day 5, confirming the cytotoxic behavior of Nar (Figure 7).   
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The combination treatment significantly reduced cell viability on days 4 and 5 
when compared to Tam only. Furthermore, our results show that Tam+Nar treatment 
elicited a more cytotoxic effect than either treatment alone.  Collectively our results 
indicate that Tam+Nar produced maximal effects on cell density and viability between 
days 4 and 5. 
 
 
 
Figure 7. Tam+Nar elicits a cytotoxic effect. MCF-7 cells were grown in full medium 
the presence of 4-OHT (100 nM), Nar, (250 μM) or a combination of the two.  Cell 
viability was determined by flow cytometry. Results are the means ± SEM of three 
independent experiments. Significance at P < 0.05 was compared to Tam on individual 
days (*). 
 
 
	  
	  
	  
	  
18	  
Determination of the optimal Tam+Nar concentration  
Next, we investigated whether a lower concentration of drugs would elicit similar 
effects as the reference (Ref) treatment (250 μM Nar and 100 nM Tam on MCF-7 cells 
on day 4). To do this, we treated MCF-7 cells with 250 μM Nar and decreasing 
concentrations of Tam for 4 days.  Cell density did not change when Tam was reduced 
during the dual treatment (Figure 8A).   
To determine the effects on cell density of a lower concentration of Nar during 
dual treatment, we treated MCF-7 cells with 100 nM Tam and decreasing concentrations 
of Nar for four days.  A combination treatment of 200 μM Nar and 100 nM Tam showed 
a minimal increase of 7% in cell density when compared to the Ref treatment (Figure 
8B). 
Next, we wanted to determine the lowest concentrations of both Nar and Tam. To 
do this, we treated cells for four days with varying concentrations of Nar and Tam. The 
optimal lowest concentration was 200 μM Nar and 25 nM Tam. The other two treatments 
showed a significant increase in cell density (Figure 8C).  
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A.  
 
B.  
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C.  
 
Figure 8.  The determination of the optimal concentration of Tam+Nar on cell 
density.   MCF-7 cells were grown in full medium the presence of varying concentrations 
of Nar and varying concentrations of 4-OHT for four days.  Cell density (cells/ml) was 
determined by flow cytometry.  Results are the means ± SEM of three independent 
experiments.  Significance at P < 0.05 was compared to Ref (*). 
 
 
 We also investigated whether a lower concentration of drugs would elicit similar 
effects the Ref treatment on cell viability.  To do this, we treated MCF-7 cells with 250 
μM Nar and decreasing concentrations of Tam for 4 days.  Reduction of Tam did not 
affect cell viability (Figure 9A). 
 Next, we investigated the effects of varying concentrations of Nar on cell viability 
while in combination with Tam.  When compared to the Ref treatment, a combination of 
200 μM Nar and 100 nM Tam showed no change in cell viability, while 100 μM Nar in 
combination with 100 nM Tam showed a significant increase in cell viability (Figure 9B). 
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 Lastly, we treated cells with varying concentrations of both agents for 4 days and 
assessed cell viability.  There was a significant increase in cell viability in Nar 
concentrations lesser than 200 μM when compared to the Ref treatment (Figure 9C).   
 Our results suggest that Nar concentration is dose dependent on cell viability and 
density after 200 μM.  Tam concentrations do not alter cell density or viability.  
Collectively, our data indicates that 25 nM Tam and 200 μM Nar is the optimal 
concentration.  From here forward, we refer to 25 nM Tam and 200 μM Nar combination 
treatment as Tam+Nar. 
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A.  
 
B.  
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C.  
 
Figure 9.  The determination of the optimal concentration of Tam+Nar on cell 
viability.   MCF-7 cells were grown in full medium the presence of varying 
concentrations of Nar and varying concentrations of 4-OHT for four days.  Cell viability 
was determined by flow cytometry.  Results are the means ± SEM of three independent 
experiments.  Significance at P < 0.05 was compared to Ref (*). 
 
 
Tam+Nar reduces expression of ERK 1/2 and AKT 
To determine the mechanism by which Nar elicits these effects on cell density and 
viability while in combination with Tam, we investigated the known targets of Nar.  Nar 
has been shown to inhibit the phosphorylation of ERK 1/2 and AKT in MCF-7 cells in 
the absence of lipophilic compounds, such as estrogen (57, 70).   In our studies, we 
wanted to simulate an environment similar to that present in vivo; so we performed our 
experiments in the presence of serum with lipophilic hormones. There are no studies 
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investigating the molecular mechanism of Nar in MCF-7 cells cultured in the presence of 
lipophilic hormones.  
To investigate the effect Tam+Nar has on ERK 1/2 and AKT, we treated MCF-7 
cells with Tam, Nar, and Tam+Nar for 4 days.  We examined the phosphorylation and 
expression levels of ERK 1/2 and AKT.  Tam treatment did not affect the expression of 
ERK 1/2 and AKT.  On the other hand, Nar and Tam+Nar significantly reduced the 
expression of ERK 1/2 and AKT when compared to control (Figure 10A, B, C).  None of 
the treatments significantly changed the phosphorylation of ERK 1/2 (Figure 10A, B) or 
the phosphorylation of AKT (Figure 10A, C) relative to total protein levels.   
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A.  
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C.  
 
Figure 10.  Nar decreases the expression of ERK 1/2 and AKT.  MCF-7 cells were 
grown in full medium in the presence of 4-OHT (25 nM), Nar (200 μM), or a 
combination of the two for 4 days. Protein lysates were prepared.  Lysates were subjected 
to SDS-PAGE and immunoblotted using antibodies against phospho-ERK 1/2, ERK 1/2, 
phospho-AKT, AKT, and actin.  Immunoblot results were quantified by densitometry 
(Panels B and C). ERK results are the means ± SEM of of four independent experiments.  
AKT results are the means ± SEM of three independent experiments. Significance at P < 
0.05 was compared to vehicle (*). 
 
 
Tam+Nar promotes apoptosis via activation of caspases 7 and 9 
 Studies have shown that Nar induces apoptosis via caspase 3 activation in Hela-
cells transfected with ERα (63,64).  Since MCF-7 cells do not express caspase 3 (65) but 
do express caspases 7 and 9, we wanted to investigate whether these caspases were 
involved in Nar induced apoptosis during Tam+Nar treatment (Figure 11A, B). Total 
caspase 9 was undetectable in Nar and Tam+Nar treated cells.  Total caspase 7 was also 
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significantly reduced during Nar and Tam+Nar treatment.  Furthermore, Tam alone has 
no effect on the expression of caspase 7 or 9.  These results show that caspase 7 and 9 are 
cleaved and activated, and that apoptosis is occurring. 
 
A.  
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B.  
 
Figure 11.  Nar promotes apoptosis via increased activation of caspases 7 and 9. 
MCF-7 cells were grown in full medium in the presence of 4-OHT  (25 nM), Nar (200 
μM), or a combination of the two for 4 days. Protein lysates were prepared.  Lysates were 
subjected to SDS-PAGE and immunoblotted using antibodies against total caspase 7, 
total caspase 9, and actin (Panel A). Caspase 7 bands were quantified using densitometry 
(Panel B). Results are the means ± SEM of three independent experiments. Significance 
at P < 0.05 was compared to vehicle (*). 
 
 
Tam+Nar influences estrogen receptor localization  
 Because both Tam and Nar are known to interact with the ERα (47-49, 56), we 
wanted to investigate the localization of ERα during the various treatments.  Previous 
studies showed that Tam induces the translocation of the ERα from the cytosol into the 
nucleus (66).  On the other hand, there have been no studies to determine the effect of 
Nar on ERα localization.   
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To investigate the localization of the ERα, we treated the cells with Tam, Nar, or 
Tam+Nar for 4 days and performed immunofluorescence (Figure 12A, B).  In untreated 
cells, ERα was distributed throughout the cytosol and the nucleus.  In Tam treated cells, 
ERα was predominately localized in the nucleus, while Nar treated cells showed an 
accumulation of ERα in the cytoplasm. Tam+Nar treated cells exhibited an even 
distribution of ERα in the nucleus and the cytoplasm, suggesting that both Nar and Tam 
independently influence the localization of ERα in the combination treatment.  
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B.  
 
Figure 12. Nar alone reduces ERα nuclear localization.  MCF-7 cells were grown in 
full medium in the presence of 4-OHT (25 nM), Nar (200 μM), or a combination of the 
two for 4 days on coverslips.  At day 4, cells were fixed with formaldehyde and subjected 
to immunofluorescence using anti-ERα and DAPI. ERα localization was determined by 
confocal microscopy (Panel A). ERα nuclear localization was quantified using intensity 
parameters (Panel B).  Results are the means ± SEM of three independent experiments.  
 
 
Nar inhibits cell proliferation and viability in Tam-R cells 
 Next, we investigated the effects of cell proliferation and viability on Tam-R 
cells.  To determine the proliferation effects of Nar on Tam-R cells, we treated Tam-R 
cells with 25nM Tam, 200 μM Nar, or Tam+Nar for four days.  As expected, Tam 
treatment had little effect on Tam-R cell density, while Nar reduced cell density by 70%.  
Tam+Nar had the same effect as Nar treated cells (Figure 13A). 
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To investigate the viability effects of Nar on Tam-R cells, Tam-R cells were treated with 
25nM Tam, 200 μM Nar, or Tam+Nar for four days.  Tam treatment had no effect on cell 
viability, while Nar treatment significantly decreased the viability of Tam-R cells.  As 
expected, Tam+Nar cells exhibited the same viability as Nar treated cells (Figure 13B). 
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B.  
 
Figure 13.  Nar impairs cell density and cell viability.  Tam-R cells were grown in full 
medium the presence of 4-OHT (25 nM), Nar (200 μM), or Tam+Nar. Cell density at day 
4 (Panel A) and cell viability (Panel B) were determined by flow cytometry. Results are 
the means ± SEM of three independent experiments. Significance at P < 0.05 was 
compared to vehicle (*). 
 
 
Tam+Nar increases the phosphorylation of AKT  
Since Tam+Nar reduced total ERK 1/2 and AKT expression in Tam-sensitive 
cells, we wanted to determine whether the optimal concentration of Tam+Nar elicits the 
same effect on Tam-R cells.  We treated Tam-R cells with Tam+Nar for 4 days, and cell 
lysates were assayed for phospho-ERK 1/2, ERK 1/2, phospho-AKT, AKT, and actin. 
Tam+Nar slightly increased the expression of ERK 1/2, while the levels of phospho-ERK 
1/2 exhibited no significant change when compared to control levels.  In contrast, the 
expression of AKT was reduced in treated cells when compared to control levels, and 
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AKT phosphorylation increased over 2 fold in Tam+Nar treated cells (Figure 14).  All 
together, these results differ remarkably from Tam sensitive cells. 
 
A.  
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B.  
 
Figure 14.  Tam+Nar increases the phosphorylation of AKT. Tam-R cells were grown 
in full medium in the presence of Tam+Nar for 4 days. Protein lysates were prepared.  
Lysates were subjected to SDS-PAGE and immunoblotted using antibodies against 
phospho-ERK 1/2, ERK 1/2 phospho-AKT, AKT, and actin (Panel A). Immunoblot 
results were quantified by densitometry (Panel B). Results are the means ± SEM of two 
independent experiments.  
 
 
In the absence of lipophilic hormones, Nar eliminates the phosphorylation of ERK 1/2 
 Our previous studies demonstrated that Nar inhibited the phosphorylation of ERK 
1/2 in charcoal-stripped media (unpublished data).  Charcoal-stripped media does not 
contain lipophilic compounds, such as as estrogen. We wanted to determine the effects of 
Tam, Nar, and Tam+Nar on phospho-ERK, total ERK, phospho-AKT, and AKT in the 
absence of estrogen.  To do this, we maintained Tam-R cells in phenol red-free medium 
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supplemented with charcoal-stripped FBS and treated cells with Tam, Nar, and Tam+Nar 
for 4 days.   
Tam treatment reduced the phosphorylation of ERK 1/2, yet increased the total 
expression of ERK 1/2.  Nar, alone and in combination, resulted in undetectable levels of 
phospho-ERK 1/2.  This results were accompanied with no change in ERK 1/2 
expression. Surprisingly, without lipophilic compounds, Tam-R cells did not activate the 
AKT pathway, and the expression of AKT was significantly decreased when compared to 
control (Figure 15). These results differ drastically from Tam-R cells grown in the 
presence of lipophilic compounds.  
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B.  
 
Figure 15. Nar eliminates the phosphorylation of ERK 1/2.  Tam-R cells were grown 
in charcoal stripped medium in the presence of 25 nM 4-OHT, 200 μM Nar, or a 
combination of 25 nM 4-OHT and 200 μM Nar.  At day 4, cells were lysed.  The protein 
lysates were subjected to SDS-PAGE and immunoblotted using antibodies against 
phospho-ERK 1/2, ERK 1/2, phospho-AKT, AKT, and actin. Results were quantified 
using densitometry (Panel B).  
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CHAPTER IV 
 
DISCUSSION 
 
 
 More than 65% of breast cancer diagnosed is ER+ (2), and Tam is the most 
prescribed anti-hormone therapy to treat this type of cancer (46).  Tam functions to arrest 
cells in G1 of the cell cycle by competing with estrogen to bind to ERα (51).  Once Tam 
is bound to ERα, the complex translocates to the nucleus, but the Tam/ ERα complex 
cannot properly bind to the ERE (47-49).  Yet, ER+ breast cancer can overcome this 
block in cell cycle progression through the activation of the PI3K and MAPK pathways.  
Because Nar has been shown to inhibit the activity of these pathways (57) and inhibit 
ERα activity (55-58), a combination of Tam and Nar has the potential to be more 
effective than Tam alone. 
 Because Tam is well studied, effects of Tam on cell density and cell viability are 
widely documented.  On the other hand, studies on Nar on these parameters are limited; 
studies have investigated the 24-hour effects of 1.0 μM (63) and 100 μM (55) Nar on 
MCF-7 cell proliferation.  Yet the prolonged (2 – 5 days) effects of Nar on MCF-7 cell 
proliferation and viability had not been determined. 
Although our studies indicate that Nar treatment alone has the ability to inhibit 
MCF-7 proliferation and reduce viability, single kinase inhibitors are rarely successful in 
a clinical setting (60). It has also been suggested that combination therapies of anti- 
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estrogen and kinase inhibitors are the future of ER+ breast cancer treatment (61).  Thus, 
we wanted to investigate the effects of a combination of Nar and Tam.   
Since Tam+Nar inhibits multiple pathways, we focused our studies on the effects 
of Nar on Tam sensitive MCF-7 cells.  Overall, our studies indicate that Tam+Nar 
inhibited MCF-7 cell density and cell viability better than Tam alone, and the greatest 
effect occurred between days 4 and 5.  To minimize undesired side effects, we 
investigated the optimal concentration of the Tam+Nar treatment on cell density and cell 
viability. The reduction of Tam concentration showed no effect on cellular proliferation 
and viability when compared to the Ref treatment.  There was a dose-dependent effect as 
Nar concentration was reduced from 200 μM to 50 μM.  Lastly, Nar concentrations were 
reduced in the presence of increasing Tam treatment.  Again, a dose dependent effect was 
observed with Nar.  Our studies show that an optimal treatment of 200 μM Nar and 25 
nM Tam for four days of treatment inhibited cellular proliferation and reduced cellular 
viability in MCF-7 cells greater than Tam alone.   Future studies could investigate lower 
concentrations of Tam on cellular proliferation and viability while combined with 200 
μM Nar.  Fewer undesired side effects could be a benefit of a lower concentration of 
Tam. 
Next, we investigated the effects of Nar on Tam-R cells, because Nar targets the 
pathways that are upregulated in Tam-R cells that allow these cells to proliferation again.   
In Tam-R cells, Tam did not affect the density or viability, as expected.  Nar and 
Tam+Nar significantly reduced cell density and viability. Studies have suggested that 
kinase inhibitors may reverse Tam-resistance (52).  Because Nar and Tam+Nar elicit the 
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same effects on Tam-R on density and viability, our results suggest that Nar does not 
recover Tam sensitivity in Tam-R cells.  Though the effects of Tam, Nar, and Tam+Nar 
on Tam-R viability (Figure 13B) do not appear as robust as the Tam-sensitive (Tam-S) 
experiment (Figure 7), the results do agree.  In Tam-R cells, the combination treatment is 
essentially the same as the Nar treatment.  Thus, in Tam-sensitive cells (Figure 7), we can 
only compare the Nar treatment on day 4 to the Tam-R experiment.  Overall, Nar elicits 
the same density and viability effects on Tam-R cells as Tam sensitive cells.   
 Because the apoptotic mechanism of Nar has never been investigated in cells that 
do not express caspase 3, we investigated the apoptotic mechanism of Tam+Nar on 
MCF-7 cells after four days.  Our results showed total reduction of full-length caspase 9, 
as well as a significant reduction in full-length caspase 7. Although we were unable to 
detect the cleaved forms of these caspases, other studies have shown that a reduction in 
full-length caspase indicates cleavage, and thus activation (67).   To investigate the 
apoptotic mechanism of Nar treatment on Tam-R cells, future studies should analyze 
levels of caspase 7 and caspase 9 in these cells. 
 Because MCF-7 cells grow primarily through the activities of the ERα, we 
wanted to investigate the effect of Nar and Tam+Nar on the localization patterns of ERα.  
In untreated cells, ERα is distributed throughout the cytoplasm and nucleus.  Nar 
sequestered ERα in the cytoplasm. Tam+Nar showed a redistribution of ERα in both the 
cytoplasm and the nucleus.  This result suggests that Tam and Nar compete with one 
another to interact with ERα.   
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 Previous studies in our lab demonstrated that Tam-R cells exhibited an even 
distribution of the ERα when treated with Tam, which is similar to localization pattern of 
ERα in untreated MCF-7 cells. Additionally, these previous studies showed that ERα is 
sequestered outside of the nucleus in Tam-R cells treated with Nar.  These results are 
similar to the ERα localization in Nar treated Tam-S MCF-7 cells.  Collectively, our 
results suggest that Nar treatment results in the accumulation the ERα in the cytoplasm. 
Next, we wanted to investigate the molecular mechanism of Tam+Nar by investigating 
the known targets of Nar, ERK 1/2 and AKT in Tam-S (MCF-7 cells) and Tam-R cells 
cultured in the presence or absence of lipophilic compounds. In Tam+Nar Tam-S cells, 
only total ERK 1/2 expression decreased.  In Tam-R cells with lipophilic hormones, only 
the phosphorylation of AKT increased 300% of untreated. When cultured without 
lipophilic compounds, Tam-R cells did not express phosphorylated AKT, but these cells 
expressed high levels of phosphorylated ERK 1/2, which confirms the estrogen-
independence in these cells. Tam+Nar treatment eliminated this phosphorylation  
(reviewed in Figure 22). 
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Figure 16.  Overview of the known targets of Nar. MCF-7 and Tam-R cells were 
grown in full medium or in charcoal stripped medium with or without a combination of 
25 nM 4-OHT and 200 μM Nar.  At day 4, cells were lysed.  The protein lysates were 
subjected to SDS-PAGE and immunoblotted using antibodies against phospho-ERK 1/2, 
ERK 1/2, phospho-AKT, AKT, and actin.  
 
 
 The mechanism for the inhibition of ERK 1/2 phosphorylation in Tam-R cells in 
the absence of estrogen is due to Nar treatment.  Tam-R cells proliferate and survive 
independent of AKT and ERα/estrogen activity.  Thus, a constitutively active ERK 1/2 
pathway in Tam-R cells is a potential mechanism used by these cells for survival. A 
constitutively active ERK 1/2 can either directly affect transcription factors to induce 
proliferation, or ERK 1/2 can phosphorylate the ERα, activating ERα transcription 
independently of ligand binding.  Because our confocal results suggest that Nar 
sequesters ERα in the cytoplasm, ERα ligand-independent transcription may not be 
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activated by ERK 1/2 during Nar treatment. Thus, without the influence of estrogen, Nar 
inhibits ERK 1/2 phosphorylation, directly affecting transcription factors that induce 
proliferation in Tam-R cells. 
 Furthermore, our results suggest that Tam+Nar impairs MCF-7 proliferation 
through the inhibition of the activity of ERα, either directly or indirectly.  Because Nar 
sequesters ERα in the cytoplasm, the ERα transcriptional activity may be reduced, and 
when Tam is bound to the ERα, ERα cannot transcribe genes.  This would explain the 
decrease in ERK and AKT proteins: both of these genes have transcription factor binding 
domains for ERα (68).  Thus, if ERα transcriptional activity is decreased, the total 
protein of its targets would be decreased as well. 
 Previous studies suggest that Nar inhibits cellular proliferation by inhibiting the 
ERα/estrogen complex from activating the MAPK and PI3K pathways (64), yet when 
estrogen is present, our immunoblot results do not indicate this. On the other hand, 
Bulzome et. al showed that concentrations of Nar higher than 0.1 μM inhibit cellular 
proliferation independent of this proposed mechanism (63).  Thus, further studies need to 
be performed to understand the underlying mechanism of a Tam+Nar combination 
treatment.    
 While Nar inhibits the phosphorylation of AKT and ERK 1/2, it is uncertain if 
this is a direct effect or if Nar is targeting a kinase upstream in these pathways.  It is also 
possible that neither is the real target eliciting these effects but just a byproduct. Future 
studies could investigate this by using combinations of ERK 1/2, MEK 1/2, AKT, and 
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PIK3 inhibitors.   These studies should be performed in stripped media to eliminate the 
endogenous activation of these pathways.  
 Overall, our studies demonstrated that Tam+Nar is an effective inhibitor of ER+ 
breast cancer cell proliferation in MCF-7 Tam-S and Tam-R cells.  Tam+Nar proved 
effective in reducing cell viability by inducing apoptosis. Although further research needs 
to be done to determine the exact mechanism of Tam+Nar in MCF-7 cells in the presence 
of estrogen, our studies suggest that ERα interactions may contribute to this mechanism.
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